Skip to main content
. 2020 Mar 18;26(4):475–485. doi: 10.1111/cns.13297

Figure 3.

Figure 3

Silencing CXCL1 attenuated the malignancy of glioma cell lines. A and B, qRT‐PCR analysis for measuring the mRNA expression of CXCL1 in U87 and U251 cells transfected with lentiviral shCXCL1#1, shCXCL1#2, and negative control. C and D, Western blot analysis for detecting the CXCL1 protein expression in U87 and U251 cells transfected with lentiviral shCXCL1#1, shCXCL1#2, and negative control. E and F, Time survival curve of U87 and U251 cells transfected with lentiviral shCXCL1#1, shCXCL1#2, and negative control (***P < .001, with one‐way ANOVA followed by Dunnett's post‐test) G, upper panel: Wound healing assays were performed to determine the inhibition of migratory ability in shCXCL1 transfected cell lines. Lower panel: Matrigel invasion assays were used to identify the inhibition of invasive ability of CXCL1 silencing in shCXCL1 transfected cell lines. H, Kaplan‐Meier analysis for in vivo intracranial xenograft mice using U87 cells pretransfected with shCXCL1#1, shCXCL2#2, and negative control (***P < .001, with log‐rank test)